BioSpace News Archive

Oncotelic Therapeutics, Inc announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on June3-6, San Diego.

BlueSphere Bio today announced that Keir Loiacono, Esq., Chief Executive Officer of BlueSphere Bio, will provide a corporate update and participate in a panel discussion at the 2024 BIO International convention being held from June 3 – 6, 2024.

MimiVax Inc announced that the United States Food and Drug Administration has awarded a supplemental orphan drug designation to MimiVax’s SurVaxM vaccine to now include malignant glioma.

The Maryland Stem Cell Research Commission announces the release of Requests for Applications for the Maryland Stem Cell Research Fund’s first funding cycle of fiscal year 2025.

Catalyst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS).

Galapagos NV and Adaptimmune Therapeutics plc announced that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune’s next-generation TCR T-cell therapy targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos’ decentralized cell manufacturing platform.

Agios Pharmaceuticals, Inc. today announced that the company is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m. ET.